Myeloma Investment Fund

Overview

The Myeloma Investment Fund (MIF) is a venture philanthropy fund dedicated to advancing new therapies for multiple myeloma patients. As a wholly owned subsidiary of the Multiple Myeloma Research Foundation (MMRF), the MIF invests in promising companies, clinical assets, and technologies in oncology to drive the development of new treatments for multiple myeloma. This evergreen fund is supported entirely by philanthropy, with all profits reinvested back into research for more effective treatments until there is a cure for every patient. The MIF collaborates closely with portfolio companies to help them advance multiple myeloma research, providing access to longstanding relationships with pharmaceutical companies and academic medical centers, a clinical network of 23 sites, and data from the largest genomics dataset of any cancer. The fund's investment strategy focuses on identifying and investing in the most promising new therapies in development and innovative technologies that could change the landscape of myeloma research. Investments are driven by the singular goal to accelerate the development of novel therapies that could lead to cures for each and every multiple myeloma patient. Since its inception, the MIF has committed over $23 million to 20 companies in its portfolio, with six treatments advanced to the clinic. The fund has invested in companies such as Reverb Therapeutics, Dynamic Cell Therapies, and KAHR, supporting the development of novel CAR T-cell technologies and immunotherapies for multiple myeloma. The MIF's impact is part of the MMRF's broader mission, which has raised over $600 million for research, opened nearly 100 clinical trials, and helped bring more than 15 FDA-approved therapies to market, tripling the life expectancy of myeloma patients. The MIF is led by Managing Director Stephanie Oestreich, Ph.D., MPA, who brings over 20 years of experience in biopharma and biotech to the role. Under her leadership, the MIF continues to drive the development of innovative treatment approaches for myeloma patients, reinforcing its commitment to advancing health equity and ensuring that all myeloma patients can benefit from scientific and clinical advances.

Investment Focus

• Focus on multiple myeloma therapies
• Innovative technologies with transformative potential
• Early-stage biotech companies
• Innovative myeloma therapies
• Clinical assets
• Oncology technologies

Portfolio Companies